Hansoh Pharma Wins Fifth China Approval for Flagship Lung Cancer Drug Ameile

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialHansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update. Hansoh Pharmaceutical announced that its innovative lung cancer drug Ameile (aumolertinib mesylate tablets) has received approval from China’s National Medical Products Administration for a fifth indication, allowing its use in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. This latest approval broadens Ameile’s clinical scope across multiple stages and treatment settings of EGFR-mutated NSCLC, reinforces the company’s position in China’s high-value oncology market, and supports its internationalization strategy following UK marketing approval under the trade name Aumseqa. The most recent analyst rating on (HK:3692) stock is a Buy with a HK$48.20 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page. More about Hansoh Pharmaceutical Group Company Limited Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company focused on developing and commercializing innovative drugs, particularly in oncology. Its portfolio includes Ameile (aumolertinib mesylate), the first domestically developed third-generation EGFR-TKI in China, with a growing range of indications targeting non-small cell lung cancer, and the company is also expanding its presence in overseas markets such as the United Kingdom. Average Trading Volume: 8,685,544 Technical Sentiment Signal: Buy Current Market Cap: HK$233.6B